Felix J. Krendl, MD

Abdominal Transplant & Hepatobiliary Surgery Fellow | New York, USA

felix.krendl@mountsinai.org | felixjkrendl.com

ORCID 0000-0001-6395-490X

Professional profile

Austrian board-certified general and visceral surgeon and New York State-licensed physician completing a fellowship in abdominal transplant and hepatobiliary surgery at the Recanati/Miller Transplantation Institute, Mount Sinai Hospital. Academic interests connect real-world liver machine-perfusion implementation with transplant oncology and human whole-organ experimentation. PhD candidate in Clinical Cancer Research at the Medical University of Innsbruck.

Professional appointments

Aug 2025–present | **Fellow in Abdominal Transplant and Hepatobiliary Surgery**

Recanati/Miller Transplantation Institute, Mount Sinai, New York, USA. Fellowship scheduled through July 2027.

Jan–Jun 2025 | **Staff Surgeon**

Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Austria.

Feb 2018–Jan 2025 | **Surgical Resident**

Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Austria.

Oct 2023–Oct 2024 | **Research Gap Year**

OrganLife – Organ Regeneration Center of Excellence, Medical University of Innsbruck, Austria.

Education

Since Oct 2022 | **PhD Student, Clinical Cancer Research**

Medical University of Innsbruck. Thesis: “NMP as a platform for oncologic assessment, treatment and transplantation.” Advisor: Assoc.-Prof. Rupert Oberhuber, PhD, FEBS.

Feb 2017–Jun 2022 | **Dr. med. dissertation — magna cum laude**

LMU Munich. Thesis: “Systematic treatment of abdominal stab wounds: High quality treatment in a low incidence environment.” Advisor: Prof. Roland Ladurner.

Oct 2010–Sep 2017 | **Medical Doctor**

LMU Munich; Zeugnis über die ärztliche Prüfung.

Selected licensure and certification

June 2025 | New York State License to Practice Medicine and Surgery

January 2025 | Board Certification in General and Visceral Surgery, Austrian Medical Chamber

July 2017 | German Approbation, Regierung von Oberbayern, Munich

RESEARCH, EDUCATION AND SERVICE

Academic activity

Research focus

- Normothermic liver machine perfusion and organ-utilization strategies
- Transplant oncology and human whole-organ cancer models
- Clinical liver transplantation, retransplantation and combined-organ transplantation
- Donation after circulatory death and transplant-program implementation
- Hepatopancreatobiliary surgery and translational oncology

Awards, grants and competitive support

2025–2027 | **Fellowship Travel Grant — €25,600**

Austrian Society of Surgery (ÖGCH). Recipient; support for fellowship training at Mount Sinai.

Sep 2025 | **Jon van Rood Award — €2,500**

Eurotransplant. “Real-world Outcomes of Normothermic Liver Machine Perfusion in Europe.”

Nov 2023 | **MUI START — €41,049**

Principal Investigator. Normothermic liver machine perfusion of explanted livers with hepatocellular carcinoma as a platform for oncologic assessment and treatment.

Apr 2022 | **Sir Peter Morris Award**

Best Systematic Review, ACADEMIA Course, Rome, Italy.

Dec 2021 | **ESOT Education Scholarship — €1,000**

HESPERIS and ACADEMIA courses, Rome, April 2022.

Jul 2021 | **Christine Vranitzky Foundation — €60,000**

Co-Principal Investigator. Normothermic machine perfusion of metastatic livers as an ex vivo tumor model. Principal Investigator: Assoc.-Prof. Rupert Oberhuber.

Teaching and society service

Teaching experience at the Medical University of Innsbruck includes the Surgical Skills Laboratory (since 2018), Abdominal Ultrasound (since 2019), and Problem Oriented Learning (since 2023). Earlier teaching includes Human Anatomy Laboratory instruction at LMU Munich (2013–2014).

Member, ILTS Basic & Translational Research Committee (2024–2026).

Professional memberships: ISS/SIC, ÖGCH, ILTS, ESOT, ATX, IHPBA, AHPBA, ESSO, and ACO-ASSO.

Selected invited talks and oral presentations

2026 | American Transplant Congress, Boston — Oral presentation on localized liver injury (“Cradle Sign”) during normothermic liver machine perfusion.

2026 | RMTI Transplant Lecture Series, Mount Sinai — “Normothermic Liver Machine Perfusion – A Transatlantic Collaboration.”

2025 | 9th Liver NMP Training Course, Innsbruck — “Principles for Establishing NMP in the Clinical Routine.”

2024 | IHPBA Congress, Cape Town, and ILTS Congress, Houston — Clinical experience following 238 normothermic liver machine-perfusion applications.

Languages

German: native | English: fluent (C1) | Spanish: basic

CLINICAL AND TRANSLATIONAL RESEARCH

Selected publications

Author lists are abbreviated. *Shared first authorship. Online publication dates are used where indicated.

1. Krendl FJ, Oberparleiter S, Ponholzer F, et al. **Implementation of a controlled DCD program in Western Austria – key considerations and insights.** *Transpl Int. 2026;39:16147.*
doi: 10.3389/ti.2026.16147

2. Aceituno L, Magyar C, Tabrizian P, et al. (including Krendl FJ). **Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.** *Aliment Pharmacol Ther. 2026 Feb 4. Online ahead of print.*
doi: 10.1111/apt.70528

3. Trebo M*, Maurer T*, Krendl FJ*, Salcher S*, et al. **Ex vivo modelling of human colorectal cancer liver metastasis by normothermic machine perfusion.** *Mol Cancer. 2025;24(1):264.*
doi: 10.1186/s12943-025-02430-7

4. Krendl FJ, Cardini B, Fodor M, et al. **Normothermic Liver Machine Perfusion At a Large European Center – Real World Outcomes Following 238 Applications.** *Ann Surg. 2025 Jan 20. Online publication.*
doi: 10.1097/SLA.0000000000006634

5. Krendl FJ*, Primavesi F*, Oberhuber R, et al. **The importance of preclinical models for cholangiocarcinoma drug discovery.** *Expert Opin Drug Discov. 2025 Jan 22.*
doi: 10.1080/17460441.2025.2457637

6. Krendl FJ, Cardini B, Zoller H, Schneeberger S, Oberhuber R. **Leveraging normothermic liver machine perfusion as a platform for oncologic assessment in cirrhotic livers.** *J Hepatol. 2025;82(1):e12–e14.*
doi: 10.1016/j.jhep.2024.08.027

7. Krendl FJ, Cardini B, Laimer G, et al. **Normothermic liver machine perfusion and successful transplantation of split liver grafts. From proof of concept to clinical implementation.** *Transplantation. 2024 Mar 29.*
doi: 10.1097/TP.0000000000004997

8. Krendl FJ*, Fodor M*, Buch ML, et al. **The BAR Score predicts and stratifies outcomes following Liver Retransplantation: Insights from a Retrospective Cohort Study.** *Transpl Int. 2024;37:12104.*
doi: 10.3389/ti.2024.12104

9. Krendl FJ, Bellotti R, Sapisochin G, et al. **Transplant oncology – Current indications and strategies to advance the field.** *JHEP Rep. 2023 Nov 16;6(2):100965. Online publication.*
doi: 10.1016/j.jhepr.2023.100965

10. Hautz T, Salcher S, Fodor M, et al. (including Krendl F). **Immune cell dynamics deconvoluted by single-cell RNA sequencing in normothermic machine perfusion of the liver.** *Nat Commun. 2023;14(1):2285.*
doi: 10.1038/s41467-023-37674-8

PubMed author search | ORCID